Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas. more
Time Frame | ANEB | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.03% | 1.96% | 1.86% |
1-Month Return | 15.77% | 1.41% | 1.29% |
3-Month Return | 22.36% | -0.06% | 4.3% |
6-Month Return | 40% | 14.64% | 19.12% |
1-Year Return | 30.87% | 9.92% | 28.17% |
3-Year Return | -57.3% | 21.12% | 30.48% |
5-Year Return | -57.61% | 76.06% | 96.57% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 173.35K | 3.61M | 3.61M | 6.83M | 11.78M | [{"date":"2019-12-31","value":1.47,"profit":true},{"date":"2020-12-31","value":30.67,"profit":true},{"date":"2021-12-31","value":30.67,"profit":true},{"date":"2022-12-31","value":57.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (173.35K) | (3.61M) | (3.61M) | (6.83M) | (11.78M) | [{"date":"2019-12-31","value":-17335000,"profit":false},{"date":"2020-12-31","value":-361375300,"profit":false},{"date":"2021-12-31","value":-361375300,"profit":false},{"date":"2022-12-31","value":-683117400,"profit":false},{"date":"2023-12-31","value":-1178359900,"profit":false}] |
Total Non-Operating Income/Expense | - | 26.63M | (26.63M) | 97.96K | 106.46K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-100.01,"profit":false},{"date":"2022-12-31","value":0.37,"profit":true},{"date":"2023-12-31","value":0.4,"profit":true}] |
Pre-Tax Income | (174.64K) | (30.25M) | (30.25M) | (6.83M) | (11.73M) | [{"date":"2019-12-31","value":-17463700,"profit":false},{"date":"2020-12-31","value":-3025255400,"profit":false},{"date":"2021-12-31","value":-3025255400,"profit":false},{"date":"2022-12-31","value":-682561900,"profit":false},{"date":"2023-12-31","value":-1173233800,"profit":false}] |
Income Taxes | (1.04K) | - | 10.75K | - | (104.19K) | [{"date":"2019-12-31","value":-9.68,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-969.49,"profit":false}] |
Income After Taxes | - | - | (30.26M) | - | (11.63M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-3026330100,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-1162814740,"profit":false}] |
Income From Continuous Operations | - | (30.25M) | (6.83M) | (11.73M) | (11.60M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3025255400,"profit":false},{"date":"2021-12-31","value":-682561900,"profit":false},{"date":"2022-12-31","value":-1173233800,"profit":false},{"date":"2023-12-31","value":-1160132600,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (174.64K) | (30.25M) | (30.26M) | (6.83M) | (11.73M) | [{"date":"2019-12-31","value":-17463700,"profit":false},{"date":"2020-12-31","value":-3025255400,"profit":false},{"date":"2021-12-31","value":-3026330100,"profit":false},{"date":"2022-12-31","value":-682561900,"profit":false},{"date":"2023-12-31","value":-1173233800,"profit":false}] |
EPS (Diluted) | - | (0.32) | (2.40) | (0.44) | (0.42) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-32.38,"profit":false},{"date":"2021-12-31","value":-240,"profit":false},{"date":"2022-12-31","value":-44,"profit":false},{"date":"2023-12-31","value":-42,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ANEB | |
---|---|
Cash Ratio | 6.56 |
Current Ratio | 6.73 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ANEB | |
---|---|
ROA (LTM) | -54.65% |
ROE (LTM) | -95.37% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ANEB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ANEB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 11.61 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Anebulo Pharmaceuticals, Inc. (ANEB) has disclosed a new risk, in the Debt & Financing category. Anebulo Pharmaceuticals, Inc. has undertaken a sig…
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three and twelve months ended June 30, 2023, and recent updates. Fourth Quarter Fiscal Year 2023 and Subsequent Highlights:
FDA provides favorable input on studies to support ANEB-001 approval Part C Extension of Phase 2 trial completed exploring THC challenge dose of up to 60 mg Anebulo Pharmaceuticals, Inc. (Nasdaq: …
Anebulo Pharmaceuticals Inc (ANEB) share price today is $2.83
Yes, Indians can buy shares of Anebulo Pharmaceuticals Inc (ANEB) on Vested. To buy Anebulo Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANEB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Anebulo Pharmaceuticals Inc (ANEB) via the Vested app. You can start investing in Anebulo Pharmaceuticals Inc (ANEB) with a minimum investment of $1.
You can invest in shares of Anebulo Pharmaceuticals Inc (ANEB) via Vested in three simple steps:
The 52-week high price of Anebulo Pharmaceuticals Inc (ANEB) is $4.05. The 52-week low price of Anebulo Pharmaceuticals Inc (ANEB) is $1.62.
The price-to-earnings (P/E) ratio of Anebulo Pharmaceuticals Inc (ANEB) is
The price-to-book (P/B) ratio of Anebulo Pharmaceuticals Inc (ANEB) is 11.61
The dividend yield of Anebulo Pharmaceuticals Inc (ANEB) is 0.00%
The market capitalization of Anebulo Pharmaceuticals Inc (ANEB) is $77.16M
The stock symbol (or ticker) of Anebulo Pharmaceuticals Inc is ANEB